论文部分内容阅读
目的探讨乳腺癌特异基因(BCSG1)在“三阴”性乳腺癌新辅助化疗疗效评估中的价值。方法采用免疫组化S-P法和荧光定量PCR方法检测32例“三阴”性乳腺癌患者新辅助化疗(CEF方案)前后乳腺癌组织BCSG1的表达,比较化疗前后肿瘤体积的变化情况,分析新辅助化疗前后BCSG1蛋白表达与肿瘤形态学变化的关系。结果23例乳腺癌患者新辅助化疗后肿瘤体积均有明显缩小,病灶缓解率(CR+PR)为84.4%;新辅助化疗后BCSG1 mRNA表达水平亦明显低于化疗前(P<0.05),BCSG1蛋白高表达率低于新辅助化疗前(P<0.01)。结论BCSG1分子和蛋白水平在“三阴”性乳腺癌新辅助化疗后均明显降低,与新辅助化疗后疗效呈负相关(r=-0.584,P<0.01),提示BCSG1可作为“三阴”乳腺癌新辅助化疗疗效的预测因子。
Objective To investigate the value of breast cancer specific gene (BCSG1) in the evaluation of the efficacy of neoadjuvant chemotherapy for “triple-yin” breast cancer. Methods The expression of BCSG1 in breast cancer tissues before and after neoadjuvant chemotherapy (CEF) was detected by immunohistochemical SP method and real-time quantitative PCR method in 32 patients with Sanyin’s breast cancer. The changes of tumor volume before and after chemotherapy were compared and analyzed Relationship between BCSG1 protein expression and tumor morphological changes before and after neoadjuvant chemotherapy. Results The tumor volume of neoadjuvant chemotherapy in 23 patients with breast cancer was significantly reduced and the remission rate (CR + PR) was 84.4%. The expression of BCSG1 mRNA in neoadjuvant chemotherapy group was significantly lower than that before chemotherapy (P <0.05) and BCSG1 The high protein expression rate was lower than that before neoadjuvant chemotherapy (P <0.01). Conclusions The expression of BCSG1 protein and protein are significantly decreased after neoadjuvant chemotherapy in patients with “Sanyin” breast cancer and negatively correlated with the efficacy of neoadjuvant chemotherapy (r = -0.584, P <0.01), suggesting that BCSG1 may be used as a “ Sanyin ”predictors of the efficacy of neoadjuvant chemotherapy in breast cancer.